Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

JR. Brown, JF. Seymour, W. Jurczak, A. Aw, M. Wach, A. Illes, A. Tedeschi, C. Owen, A. Skarbnik, D. Lysak, KS. Eom, M. Šimkovič, MA. Pavlovsky, AP. Kater, B. Eichhorst, K. Miller, V. Munugalavadla, T. Yu, M. de Borja, P. Ghia, AMPLIFY...

. 2025 ; 392 (8) : 748-762. [pub] 20250205

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze III, multicentrická studie, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009841
E-zdroje Online Plný text

NLK ProQuest Central od 1980-01-03 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest) od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci

Odkazy

PubMed 39976417
DOI 10.1056/nejmoa2409804
Knihovny.cz E-zdroje

BACKGROUND: Whether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. METHODS: In this phase 3, open-label trial, we included patients 18 years of age or older who had an Eastern Cooperative Oncology Group performance-status score of 0 to 2 (range, 0 to 5, with higher numbers indicating greater disability) and who did not have a 17p deletion or TP53 mutation. Patients were randomly assigned, in a 1:1:1 ratio, to receive acalabrutinib-venetoclax (acalabrutinib, cycles 1 to 14; venetoclax, cycles 3 to 14), acalabrutinib-venetoclax-obinutuzumab (as above, plus obinutuzumab, cycles 2 to 7), or chemoimmunotherapy with the investigator's choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab (cycles 1 to 6). The primary end point was progression-free survival (acalabrutinib-venetoclax vs. chemoimmunotherapy) in the intention-to-treat population, assessed by blinded independent central review. RESULTS: A total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib-venetoclax, 286 acalabrutinib-venetoclax-obinutuzumab, and 290 chemoimmunotherapy (of whom 143 received fludarabine-cyclophosphamide-rituximab and 147 bendamustine-rituximab). The median age of the patients was 61 years (range, 26 to 86), 64.5% were men, and 58.6% had unmutated IGHV. Estimated 36-month progression-free survival at a median follow-up of 40.8 months was 76.5% with acalabrutinib-venetoclax, 83.1% with acalabrutinib-venetoclax-obinutuzumab, and 66.5% with chemoimmunotherapy (hazard ratio for disease progression or death with acalabrutinib-venetoclax vs. chemoimmunotherapy, 0.65 [95% confidence interval {CI}, 0.49 to 0.87], P = 0.004; for the comparison of acalabrutinib-venetoclax-obinutuzumab with chemoimmunotherapy, P<0.001). Estimated 36-month overall survival was 94.1% with acalabrutinib-venetoclax, 87.7% with acalabrutinib-venetoclax-obinutuzumab, and 85.9% with chemoimmunotherapy. Neutropenia, the most common adverse event of clinical interest of grade 3 or higher, was reported in 32.3%, 46.1%, and 43.2% in the three groups, respectively; death from coronavirus disease 2019 was reported in 10, 25, and 21 patients in the three groups. CONCLUSIONS: Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009841
003      
CZ-PrNML
005      
20250429134754.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1056/NEJMoa2409804 $2 doi
035    __
$a (PubMed)39976417
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Brown, Jennifer R $u Dana-Farber Cancer Institute, Boston $1 https://orcid.org/0000000320404961
245    10
$a Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia / $c JR. Brown, JF. Seymour, W. Jurczak, A. Aw, M. Wach, A. Illes, A. Tedeschi, C. Owen, A. Skarbnik, D. Lysak, KS. Eom, M. Šimkovič, MA. Pavlovsky, AP. Kater, B. Eichhorst, K. Miller, V. Munugalavadla, T. Yu, M. de Borja, P. Ghia, AMPLIFY investigators, AMPLIFY Investigators
520    9_
$a BACKGROUND: Whether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. METHODS: In this phase 3, open-label trial, we included patients 18 years of age or older who had an Eastern Cooperative Oncology Group performance-status score of 0 to 2 (range, 0 to 5, with higher numbers indicating greater disability) and who did not have a 17p deletion or TP53 mutation. Patients were randomly assigned, in a 1:1:1 ratio, to receive acalabrutinib-venetoclax (acalabrutinib, cycles 1 to 14; venetoclax, cycles 3 to 14), acalabrutinib-venetoclax-obinutuzumab (as above, plus obinutuzumab, cycles 2 to 7), or chemoimmunotherapy with the investigator's choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab (cycles 1 to 6). The primary end point was progression-free survival (acalabrutinib-venetoclax vs. chemoimmunotherapy) in the intention-to-treat population, assessed by blinded independent central review. RESULTS: A total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib-venetoclax, 286 acalabrutinib-venetoclax-obinutuzumab, and 290 chemoimmunotherapy (of whom 143 received fludarabine-cyclophosphamide-rituximab and 147 bendamustine-rituximab). The median age of the patients was 61 years (range, 26 to 86), 64.5% were men, and 58.6% had unmutated IGHV. Estimated 36-month progression-free survival at a median follow-up of 40.8 months was 76.5% with acalabrutinib-venetoclax, 83.1% with acalabrutinib-venetoclax-obinutuzumab, and 66.5% with chemoimmunotherapy (hazard ratio for disease progression or death with acalabrutinib-venetoclax vs. chemoimmunotherapy, 0.65 [95% confidence interval {CI}, 0.49 to 0.87], P = 0.004; for the comparison of acalabrutinib-venetoclax-obinutuzumab with chemoimmunotherapy, P<0.001). Estimated 36-month overall survival was 94.1% with acalabrutinib-venetoclax, 87.7% with acalabrutinib-venetoclax-obinutuzumab, and 85.9% with chemoimmunotherapy. Neutropenia, the most common adverse event of clinical interest of grade 3 or higher, was reported in 32.3%, 46.1%, and 43.2% in the three groups, respectively; death from coronavirus disease 2019 was reported in 10, 25, and 21 patients in the three groups. CONCLUSIONS: Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.).
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x mortalita $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a pyraziny $x škodlivé účinky $x aplikace a dávkování $7 D011719
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    12
$a doba přežití bez progrese choroby $7 D000077982
650    12
$a benzamidy $x škodlivé účinky $x aplikace a dávkování $7 D001549
650    12
$a sulfonamidy $x aplikace a dávkování $x škodlivé účinky $7 D013449
650    12
$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283
650    12
$a bicyklické sloučeniny heterocyklické $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D019086
650    12
$a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $7 D003520
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a vidarabin $x analogy a deriváty $x aplikace a dávkování $x škodlivé účinky $7 D014740
650    _2
$a dospělí $7 D000328
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Seymour, John F $u Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia $u Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia $1 https://orcid.org/0000000321886835
700    1_
$a Jurczak, Wojciech $u Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland
700    1_
$a Aw, Andrew $u University of Ottawa, Ottawa
700    1_
$a Wach, Malgorzata $u Medical University of Lublin, Lublin, Poland
700    1_
$a Illes, Arpad $u Faculty of Medicine, Division of Hematology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary
700    1_
$a Tedeschi, Alessandra $u ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan
700    1_
$a Owen, Carolyn $u University of Calgary, Calgary, AB, Canada
700    1_
$a Skarbnik, Alan $u Novant Health Cancer Institute, Charlotte, NC
700    1_
$a Lysak, Daniel $u Fakultní Nemocnice Plzen, Pilsen, Czech Republic
700    1_
$a Eom, Ki-Seong $u Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, South Korea
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000303315334 $7 xx0117538
700    1_
$a Pavlovsky, Miguel Arturo $u FUNDALEU, Clinical Research Center, Buenos Aires
700    1_
$a Kater, Arnon Philip $u Amsterdam University Medical Centers, University of Amsterdam, Amsterdam
700    1_
$a Eichhorst, Barbara $u University Hospital Cologne, Cologne, Germany
700    1_
$a Miller, Kara $u AstraZeneca, South San Francisco, CA
700    1_
$a Munugalavadla, Veerendra $u AstraZeneca, South San Francisco, CA
700    1_
$a Yu, Ting $u AstraZeneca, South San Francisco, CA
700    1_
$a de Borja, Marianne $u AstraZeneca, Mississauga, ON, Canada
700    1_
$a Ghia, Paolo $u Università Vita-Salute San Raffaele, Milan $u IRCCS Ospedale San Raffaele, Milan
710    2_
$a AMPLIFY investigators
710    2_
$a AMPLIFY Investigators
773    0_
$w MED00003517 $t The New England journal of medicine $x 1533-4406 $g Roč. 392, č. 8 (2025), s. 748-762
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39976417 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134750 $b ABA008
999    __
$a ok $b bmc $g 2311306 $s 1246922
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 392 $c 8 $d 748-762 $e 20250205 $i 1533-4406 $m The New England journal of medicine $n N Engl J Med $x MED00003517
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace